Skip to content
Clinical trial Open access

Steady-State Pharmacokinetic Drug–Drug Interaction Study of Zastaprazan, a Novel Potassium-Competitive Acid Blocker, and Atorvastatin in Healthy Participants

Oct 2026 · Drug Design, Development and Therapy · Vol 20, pp. 1-11 · 0 citations · 17 references
Medicine

TL;DR

Although atorvastatin reduced zastaprazan Cmax,ss, total exposure was preserved, a pattern consistent with altered absorption kinetics without establishing a specific mechanism, and pharmacokinetic findings do not suggest a need for atorvastatin dose adjustment under the studied conditions.

Abstract

Purpose Zastaprazan is a novel potassium-competitive acid blocker with CYP3A-mediated metabolism, whereas atorvastatin undergoes CYP3A4- and transporter-mediated disposition. Because these drugs may be co-administered and their net interaction cannot be inferred from shared metabolic pathways alone, this study evaluated their steady-state pharmacokinetic drug–drug interaction. Participants and Methods This open-label, fixed-sequence, three-period, multiple-dose study included healthy Korean men. Participants received atorvastatin 40 mg once daily, zastaprazan 20 mg once daily, and concomitant atorvastatin and zastaprazan, each for 5 consecutive days, under steady-state conditions. Plasma concentrations of zastaprazan, atorvastatin, and 2-hydroxyatorvastatin were measured, and geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated for Cmax,ss and AUCτ,ss. Results Twenty-four healthy Korean men received at least one dose of a study drug, and 22 were included in the pharmacokinetic analysis. Atorvastatin decreased zastaprazan Cmax,ss by approximately 26% (GMR, 0.740; 90% CI, 0.655–0.836), whereas AUCτ,ss was preserved (GMR, 1.054; 90% CI, 0.927–1.198). Zastaprazan did not meaningfully alter atorvastatin exposure (Cmax,ss GMR, 0.982; 90% CI, 0.806–1.195; AUCτ,ss GMR, 1.029; 90% CI, 0.944–1.122). The AUCτ,ss of 2-hydroxyatorvastatin showed a modest decrease (GMR, 0.940; 90% CI, 0.889–0.994) that remained within the predefined conventional reference range. Co-administration was generally well tolerated, with no serious adverse events or adverse event-related discontinuations. Conclusion Zastaprazan did not meaningfully alter atorvastatin Cmax,ss or AUCτ,ss under the studied conditions. Although atorvastatin reduced zastaprazan Cmax,ss, total exposure was preserved, a pattern consistent with altered absorption kinetics without establishing a specific mechanism. The pharmacodynamic significance of the lower zastaprazan Cmax,ss remains uncertain because intragastric pH was not measured. These pharmacokinetic findings do not suggest a need for atorvastatin dose adjustment under the studied conditions.

Read PDF

Similar papers

Clinical trial Open access Oct 2026

Effect of Food on the Pharmacokinetics, Pharmacodynamics, and Safety of Zastaprazan, a Potassium‐Competitive Acid Blocker, in Healthy Participants

ABSTRACT Zastaprazan (JP‐1366) is a novel potassium‐competitive acid blocker characterized by rapid onset and sustained acid suppression. This study aimed to evaluate the effect of food on the pharmacokinetics (PK), pharmacodynamics (PD), and safety of zastaprazan in healthy participants. In this randomized, open‐label...

Hyoeun Lee, Seok-Kyu Yoon, Soo-Min Jung et al. · 0 citations
Open access Oct 2026

Pharmacokinetic and pharmacodynamic interaction of enavogliflozin, a sodium-glucose cotransporter 2 inhibitor, with glimepiride and metformin in healthy participants.

AIMS Enavogliflozin, a sodium-glucose cotransporter 2 inhibitor, is expected to be coadministered with antihyperglycaemic drugs with different mechanisms of action. This study aimed to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between enavogliflozin, glimepiride and metformin. METHODS...

Kyung-Moon Chang, Yoonjin Kim, Da-Ye Jung et al. · 0 citations
Clinical trial Open access Sep 2026

Pharmacokinetic and Pharmacodynamic Drug‐Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single‐Center, Single‐Arm, Phase I Study in China

Abstract This single‐center, single‐arm, Phase I study evaluated drug–drug interactions (DDIs) between cofrogliptin and metformin in healthy Chinese subjects. Twenty‐two subjects sequentially received metformin monotherapy (Days 1–4), cofrogliptin monotherapy (Days 6–34), and combination therapy (Days 38–47). Serial bl...

Cheng Cui, Na Liu, Chang Chu et al. · 0 citations
Oct 2026

Food-associated pharmacokinetic differences and variability of a rosuvastatin/ezetimibe fixed-dose combination in replicated bioequivalence studies.

BACKGROUND /OBJECTIVES Rosuvastatin/ezetimibe fixed-dose combinations target cholesterol synthesis and intestinal absorption, but pharmacokinetics may differ by analyte, endpoint, and fasted/fed state. This study characterized food-associated pharmacokinetic differences, reference-product within-subject variability, an...

Xing-Wei Liu, Lu Bai, Qian Li et al. · 0 citations
Clinical trial Open access Nov 2026

Drug-Drug Interaction Assessment of WXFL10203614 With Rifampicin, Itraconazole and Metformin: A Three-Cohort Phase I Study.

To evaluate the effects of rifampicin and itraconazole on the pharmacokinetics (PK) of the Janus kinase 1 (JAK1) inhibitor WXFL10203614 and the effects of steady-state WXFL10203614 on metformin PK and safety. In this single-center, open-label, fixed-sequence, self-controlled Phase I study, 54 healthy participants were...

Jin-Mei Zhou, Meng-Shuang Gao, Dao-Lei Zhou et al. · 0 citations
Open access Sep 2026

Bioequivalence Assessment of Sitagliptin/Metformin Extended-Release Fixed-Dose Combinations in Healthy Mexican Subjects Under Fasting and Fed Conditions

Background/Objectives: Management of Type 2 Diabetes (T2D) frequently requires combination therapy. Fixed-dose combinations (FDCs) of sitagliptin and extended-release (ER) metformin improve therapeutic adherence but pose biopharmaceutical challenges related to matrix robustness and food–drug interactions. This study ev...

Omar Emmanuel Hernández Piña, Porfirio de la Cruz-Cruz, Erika Gabriela Guido Ávila et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.